These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria. Adoke Y; Zoleko-Manego R; Ouoba S; Tiono AB; Kaguthi G; Bonzela JE; Duong TT; Nahum A; Bouyou-Akotet M; Ogutu B; Ouedraogo A; Macintyre F; Jessel A; Laurijssens B; Cherkaoui-Rbati MH; Cantalloube C; Marrast AC; Bejuit R; White D; Wells TNC; Wartha F; Leroy D; Kibuuka A; Mombo-Ngoma G; Ouattara D; Mugenya I; Phuc BQ; Bohissou F; Mawili-Mboumba DP; Olewe F; Soulama I; Tinto H; Malar J; 2021 May; 20(1):222. PubMed ID: 34011358 [TBL] [Abstract][Full Text] [Related]
8. Spiroindolone KAE609 for falciparum and vivax malaria. White NJ; Pukrittayakamee S; Phyo AP; Rueangweerayut R; Nosten F; Jittamala P; Jeeyapant A; Jain JP; Lefèvre G; Li R; Magnusson B; Diagana TT; Leong FJ N Engl J Med; 2014 Jul; 371(5):403-10. PubMed ID: 25075833 [TBL] [Abstract][Full Text] [Related]
9. A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. Macintyre F; Adoke Y; Tiono AB; Duong TT; Mombo-Ngoma G; Bouyou-Akotet M; Tinto H; Bassat Q; Issifou S; Adamy M; Demarest H; Duparc S; Leroy D; Laurijssens BE; Biguenet S; Kibuuka A; Tshefu AK; Smith M; Foster C; Leipoldt I; Kremsner PG; Phuc BQ; Ouedraogo A; Ramharter M; BMC Med; 2017 Oct; 15(1):181. PubMed ID: 28988541 [TBL] [Abstract][Full Text] [Related]
10. Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. White NJ; Duong TT; Uthaisin C; Nosten F; Phyo AP; Hanboonkunupakarn B; Pukrittayakamee S; Jittamala P; Chuthasmit K; Cheung MS; Feng Y; Li R; Magnusson B; Sultan M; Wieser D; Xun X; Zhao R; Diagana TT; Pertel P; Leong FJ N Engl J Med; 2016 Sep; 375(12):1152-60. PubMed ID: 27653565 [TBL] [Abstract][Full Text] [Related]
11. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Charman SA; Arbe-Barnes S; Bathurst IC; Brun R; Campbell M; Charman WN; Chiu FC; Chollet J; Craft JC; Creek DJ; Dong Y; Matile H; Maurer M; Morizzi J; Nguyen T; Papastogiannidis P; Scheurer C; Shackleford DM; Sriraghavan K; Stingelin L; Tang Y; Urwyler H; Wang X; White KL; Wittlin S; Zhou L; Vennerstrom JL Proc Natl Acad Sci U S A; 2011 Mar; 108(11):4400-5. PubMed ID: 21300861 [TBL] [Abstract][Full Text] [Related]
12. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. Thriemer K; Degaga TS; Christian M; Alam MS; Rajasekhar M; Ley B; Hossain MS; Kibria MG; Tego TT; Abate DT; Weston S; Mnjala H; Rumaseb A; Satyagraha AW; Sadhewa A; Panggalo LV; Ekawati LL; Lee G; Anose RT; Kiros FG; Simpson JA; Karahalios A; Woyessa A; Baird JK; Sutanto I; Hailu A; Price RN Lancet; 2023 Dec; 402(10417):2101-2110. PubMed ID: 37979594 [TBL] [Abstract][Full Text] [Related]
13. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Commons RJ; Simpson JA; Thriemer K; Hossain MS; Douglas NM; Humphreys GS; Sibley CH; Guerin PJ; Price RN Lancet Infect Dis; 2019 Jan; 19(1):91-101. PubMed ID: 30587297 [TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study. McCarthy JS; Yalkinoglu Ö; Odedra A; Webster R; Oeuvray C; Tappert A; Bezuidenhout D; Giddins MJ; Dhingra SK; Fidock DA; Marquart L; Webb L; Yin X; Khandelwal A; Bagchus WM Lancet Infect Dis; 2021 Dec; 21(12):1713-1724. PubMed ID: 34715032 [TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. McCarthy JS; Lotharius J; Rückle T; Chalon S; Phillips MA; Elliott S; Sekuloski S; Griffin P; Ng CL; Fidock DA; Marquart L; Williams NS; Gobeau N; Bebrevska L; Rosario M; Marsh K; Möhrle JJ Lancet Infect Dis; 2017 Jun; 17(6):626-635. PubMed ID: 28363636 [TBL] [Abstract][Full Text] [Related]